DNA Damage inducible Transcript 4 Gene: The Switch of the Metabolism as Potential Target in Cancer
Ver/
Descargar
(application/pdf: 1.960Mb)
(application/pdf: 1.960Mb)
Fecha
2018Autor(es)
Fajardo, Williams
Metadatos
Mostrar el registro completo del ítemResumen
DNA damage inducible transcript 4 (DDIT4) gene is expressed under stress situations
turning off the metabolic activity triggered by the mammalian target of rapamycin (mTOR).
Several in vitro and in vivo works have demonstrated the ability of DDIT4 to generate resistance
to cancer therapy. The link between the metabolism suppression and aggressiveness
features of cancer cells remains poorly understood since anti-mTOR agents who are part
of the repertoire of drugs used for systemic treatment of cancer achieving variable results.
Interestingly, the high DDIT4 expression is associated with worse outcomes compared
to tumors with low DDIT4 expression, seen in a wide variety of solid and hematological
tumors, which suggests the driver role of this gene and provide the basis to target it as
part of a new therapeutic strategy. In this review, we highlight our current knowledge about
the biology of DDIT4 and its role as a prognostic biomarker, encompassing the motives for
the development of target drugs against DDIT4 as a better target than mTOR inhibitors.
Palabras clave
Colecciones
El ítem tiene asociados los siguientes ficheros de licencia: